Health and Healthcare

Will Medicines Co Be the Next Target of Novartis?

Thinkstock

Medicines Co. (NASDAQ: MDCO) shares shot up on Tuesday after it was reported that Novartis A.G. (NYSE: NVS) might be eyeing this company as its newest acquisition.

Currently, Medicines has a market cap of $5.5 billion, after seeing shares nearly quadruple in 2019 alone, including Tuesday’s move. With growth like this, Medicines could fetch an even higher price, should it be acquired.

However, this wouldn’t be a problem for Novartis, which boasts a $203 billion market cap and $8.38 billion in cash and cash equivalents on the balance sheet.

Novartis appears to be targeting Medicines for its top drug candidate, a cholesterol-lowering drug for heart patients called inclisiran.

Historically, Novartis has had a strong cardiovascular drug franchise, but the firm lost ground when Diovan, once a $6 billion-per-year seller, lost patent protection in 2012, leaving the company without an immediate, innovative follow-up product.

Apart from this, Novartis has been building up its portfolio, which now includes Entresto, a $1 billion seller for heart failure, as well as an experimental RNA-targeting molecule from Ionis Pharmaceuticals that it licensed earlier this year for $150 million.

Shares of Medicines traded up about 23% to $71.96 Tuesday morning, in a 52-week range of $16.69 to $73.85. The consensus price target is $69.77.

Novartis was relatively flat at $89.98 a share. The 52-week range is $73.54 to $95.00, and the consensus price target is $101.00.


Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.